Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years

Affiliations

• ¹ Medical Clinic 5, Klinikum Dresden-Neustadt, Dresden, Germany.
• ² Department of GMP Process Development/ATMP Design, Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
• ³ Department of Internal Medicine III, Klinikum Chemnitz gGmbH, Flemmingstrasse 1, 09116, Chemnitz, Germany.
• ⁴ Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU, Dresden, Germany.
• ⁵ Klinikum Nuernberg, Paracelsus Medical Private University, Medical Clinic 5, Nuremberg, Germany.
• ⁶ Department of Internal Medicine III, Klinikum Chemnitz gGmbH, Flemmingstrasse 1, 09116, Chemnitz, Germany. m.haenel@skc.de.